Explore treatment pathways for hepatocellular carcinoma (HCC) and cholangiocarcinoma from early-stage to advanced disease.
Free to use — Live data from ClinicalTrials.gov — Updated hourly
Answer a few questions about your condition and we'll match you to the most relevant clinical trials.
See where clinical trials fit into your treatment journey
Localised tumour amenable to surgery or ablation
Standard: Surgical resection, liver transplant, or radiofrequency ablation
Multifocal disease without extrahepatic spread
Standard: Transarterial chemoembolisation (TACE)
Unresectable or metastatic hepatocellular carcinoma
Standard: Atezolizumab + Bevacizumab (immunotherapy + anti-VEGF)
Bile duct cancer with targeted therapy opportunities
Standard: Chemotherapy ± targeted therapy (FGFR/IDH1 inhibitors)
Found in ~10-15% of intrahepatic cholangiocarcinomas. FGFR inhibitors (Pemigatinib, Futibatinib) are approved and newer trials explore next-generation FGFR inhibitors.
Present in ~20% of cholangiocarcinomas. Ivosidenib targets mutant IDH1 and clinical trials explore IDH1 inhibitor combinations.
A tumour marker elevated in many HCC patients. Used for monitoring and some trials specifically target AFP-positive tumours.
Liver tumours are highly vascular. Anti-VEGF therapies (Bevacizumab, Ramucirumab) are key components of treatment, especially in combination with immunotherapy.
Loading trials from ClinicalTrials.gov...
Yes. Atezolizumab + Bevacizumab is now the 1st-line standard for advanced HCC. Many trials explore new immunotherapy combinations, including dual checkpoint inhibitors and combinations with targeted therapies.
FGFR2 fusion-positive cholangiocarcinoma can be treated with Pemigatinib or Futibatinib. IDH1-mutant disease responds to Ivosidenib. BRAF V600E mutations can be targeted with dabrafenib + trametinib. Clinical trials offer access to newer agents.
Early-stage liver cancer can potentially be cured with surgery or transplant. For advanced disease, clinical trials aim to extend life and improve quality of life. Some newer immunotherapy combinations have shown promising long-term responses.
Use our search above to find trials that match your condition and location. Review the eligibility criteria carefully.
Talk to your GP or specialist about any trials you are interested in. They can help determine if a trial is appropriate for you.
Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing. They will guide you through screening.
If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.